



ASX : IPD

12 January 2009

ASX ANNOUNCEMENT/MEDIA RELEASE

American Breast Surgeons Board Member and ImpediMed's L-Dex™ Devices Featured In Arizona Daily Star Article On Early Detection Of Lymphoedema

ImpediMed Limited announce for the information of shareholders that an article discussing the importance of early detection of lymphoedema was published online in the Arizona Daily Star on the 2nd January 2009. The article features an interview with Dr Eric B. Whitacre, who is a board member of the American Society of Breast Surgeons and director of the Breast Center of Southern Arizona, and explains his decision to use an L-Dex device in his center.

The article may be accessed at: <http://www.azstarnet.com/sn/byauthor/274157>

For more information contact:

Greg Brown ImpediMed Limited - CEO Office: +61-7-38603700

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit www.impedimed.com.

ENDS